



an Open Access Journal by MDPI

## Advanced Research in Arrhythmogenic Cardiomyopathy

Guest Editor:

### Dr. Stephen P. Chelko

Department of Biomedical  
Sciences, Florida State University  
College of Medicine, Tallahassee,  
FL, USA

Deadline for manuscript  
submissions:

**closed (31 August 2024)**

### Message from the Guest Editor

Arrhythmogenic cardiomyopathy (ACM) is a leading cause of sudden cardiac death (SCD) and a familial, non-ischemic heart disease that can affect both the left and right ventricles. ACM is often considered a “disease of the cardiac desmosome,” as over 60% of cases are associated with pathogenic desmosomal variants. Clinical characteristics involve cardiac dysfunction and increased arrhythmia, whereas pathological traits include myocardial inflammation and fibrofatty replacement of the myocardium. Exercise is a known contributor to disease progression, and patients with ACM are advised against high-intensity exercise or complete exercise cessation. Antiarrhythmics are the mainstay in ACM therapeutics, with treatment strategies directed at preventing fatal ventricular arrhythmias (FVAs) and aborting SCD. The most effective intervention is an implantable cardiac defibrillator, yet this does not prevent pathological disease progression. Recent advancements in therapeutics, albeit often in animal models of ACM, suggest that alternative therapeutics such as gene therapy may prevent these pathological hallmarks and thus avert cardiac dysfunction.



[mdpi.com/si/146790](https://mdpi.com/si/146790)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)